- Home
- BRNS vs PMVP Comparison
BRNS vs PMVP Comparison
Compare BRNS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRNS | PMVP |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 66.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BRNS | PMVP |
|---|---|---|
| Price | $0.71 | $1.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $5.00 |
| AVG Volume (30 Days) | 75.2K | ★ 269.9K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1766.46 | N/A |
| 52 Week Low | $0.64 | $0.81 |
| 52 Week High | $2.92 | $1.84 |
Technical Indicators
Market Signals| Indicator | BRNS | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 47.47 |
| Support Level | $0.68 | $1.20 |
| Resistance Level | $0.74 | $1.25 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 48.02 | 70.27 |
Price Performance
Historical ComparisonAbout BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.